Mark Lanasa: Positive CHMP opinion for BeOne Medicines’ first-line immunotherapy in ES-SCLC
Mark Lanasa, SVP, Chief Medical Officer, of Solid Tumors at BeOne Medicines, shared a post on LinkedIn by BeOne Medicines, adding:
“The exciting news of a positive CHMP opinion for our immunotherapy as a first-line treatment in extensive-stage small cell lung cancer (ES-SCLC) is so timely after my visit to Paris last week to participate in the European Lung Cancer Congress.
In my discussions with European physicians at the meeting, the conversations often turned to the substantial residual unmet need in this devastating disease.
I am thankful to our BeOne Medicines teams who are driving our efforts in SCLC and pushing the boundaries of what’s possible in oncology.”
Quoting BeOne Medicines’ post:
“News for Investors and Media: The European Medicines Agency’s CHMP issued a positive opinion recommending approval of our immunotherapy as a first-line treatment for extensive-stage small cell lung cancer (SCLC).
As an aggressive cancer with low survival rates, SCLC – which accounts for 15% of all lung cancers – is difficult to treat and new options for patients are needed.
This recommendation highlights our commitment to focusing our R&D efforts on cancers with the highest unmet need and the greatest opportunity to make an impact for patients.”
More posts featuring Mark Lanasa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023